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ABSTRACT  
Vitiligo is a hypomelanotic autoimmune skin disease arising from a breakdown in 
immunological self-tolerance, which leads to aberrant immune responses against melanocytes. 
Regulatory T cells (Tregs) are crucial to the development of self-tolerance and so are major foci 
in the study of autoimmune pathogenesis of vitiligo. This review will summarise recent findings 
concerning the role of Tregs in the pathogenesis of vitiligo. In addition, as antigen-specific Tregs 
are a potential route for the reinstatement of immune tolerance, new strategies that expand or 
induce de novo generation of Tregs and which are currently being investigated as therapies for 
other autoimmune diseases, will be discussed. These approaches will highlight the 
opportunities for Treg cell-based therapeutics in vitiligo. 
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1. Introduction 
 
Vitiligo is a hypomelanotic autoimmune skin disease resulting from loss of functional 
melanocytes from the skin with a prevalence of 1-2% [1]. The disease can affect individuals of 
any race or sex and manifests before the age of 20 years in approximately half of all cases [1]. 
Although vitiligo might be considered a minor disorder, the psychological effects of the disease 
are frequently considerable. Individuals with the disease may experience feelings of stress, 
embarrassment, self-consciousness and low self-esteem particularly when in professional or 
social situations [2]. This is particularly the case in people with darkly pigmented skin where the 
appearance of depigmented patches is very prominent and also where vitiligo develops on 
visible areas of the body such as the face, hands and arms [3]. To date, no universally effective 
and safe therapy for the disease exists. Many treatment options have been developed, but 
challenges persist as not all patients respond to the available therapies, relapse is common and 
complete repigmentation is rarely accomplished [4]. 
The exact aetiology and detailed pathogenesis of vitiligo is not fully understood, but 
autoimmunity has been strongly implicated in the development of the disease [5]. The current 
 ‘ƐƚĂƚĞ-of-the-Ăƌƚ ?ƚŚŝŶŬŝŶŐŝƐƐƵŵŵĂƌŝƐĞĚŝŶƚhe convergence theory which suggests that several 
factors can act synergistically or independently to induce the disappearance of melanocytes 
from the skin [5]. In the elicitation phase of vitiligo, triggers including physical trauma to the 
skin, emotional stresses, and imbalances of endogenous neural factors, metabolites or 
hormones lead to oxidative stress within melanocytes which then respond by actively secreting 
heat-shock protein 70 and chaperoned melanocyte antigens [6]. During the immune activation 
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stage, ƚŚĞƐĞ ‘ĚĂŶŐĞƌ ?ƐŝŐŶĂůƐƉƌŽŵŽƚĞƚŚĞĂĐƚŝǀĂƚŝŽŶŽĨĂŶƚŝŐĞŶ-presenting dendritic cells with 
the subsequent activation and recruitment of anti-melanocyte autoreactive cytotoxic T 
lymphocytes to the skin [7] (Fig. 1). 
The importance of autoimmunity in the aetiology of vitiligo is backed by recently 
identified susceptibility genes which include those involved in regulating the immune response 
such as PTPN22, CTLA-4, FOXP1, and those encoding certain major histocompatibility complex 
antigen specificities [8]. In addition, several studies have identified a pivotal role for cytotoxic T 
cells in inducing melanocyte-specific destruction in vitiligo [7], including the findings that CD8
+
 T 
cells isolated from vitiligo skin are cytotoxic to melanocytes, recognise melanocyte-specific 
autoantigens [7], and induce autologous melanocyte apoptosis through IL-6 and IL-13 [9] (Fig. 
1). In addition, there is a global expansion and widespread activation of the CD8
+
 T cell 
population in vitiligo patients [10-12]. So far, however, the exact mechanisms underlying the 
induction and activation of autoreactive CD8
+
 T cells and the loss of tolerance to melanocyte 
autoantigens in vitiligo are not clear, but as with other autoimmune disorders, it seems likely 
that this loss of tolerance to self must involve some defect in regulatory T cell (Tregs) function 
[10,11,13]. 
Regulatory T cells are a subset of CD4
+
 lymphocytes that play a key role in maintaining 
peripheral tolerance in vivo through the active suppression of self-reactive T cell activation and 
expansion (Fig. 1) [14]. They maintain order in the immune system by enforcing a dominant 
negative regulation on other immune cells including actively suppressing the activation and 
expansion of autoreactive T cells that have escaped clonal deletion in the thymus [14]. 
According to their site of maturation, two classes of Treg cells have been identified: natural 
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Tregs (nTregs) and inducible Tregs (iTregs) [15]. Natural Tregs originate from the thymus as 
CD4
+
 cells expressing high levels of CD25 together with the transcription factor and lineage 
marker FoxP3. They represent approximately 5 ?10% of the total CD4+ T cell population and 
are positively selected thymocytes with a relatively high avidity for self-antigens [15]. 
Inducible Tregs originate from the thymus as single CD4
+
 cells and differentiate into CD25
+
 
and FoxP3
+
 iTregs following adequate antigenic stimulation in the presence of cognate 
antigen and cytokines such as transforming growth factor-ɴ (TGF-ɴ), and interleukin (IL)-10 
[15]. Inhibition of effector T cells proceeds via cell-cell contact or via the secretion of inhibitory 
cytokines, mainly TGF-ɴ[15].  
This review will address recent findings concerning the role of Tregs in the pathogenesis 
of vitiligo. In addition, as antigen-specific Tregs are a potential route for the reinstatement of 
immune tolerance, new strategies which expand or induce de novo generation of Tregs and 
which are currently being investigated as therapies for other autoimmune diseases, will be 
discussed and will highlight the opportunities for Treg-based therapeutics in vitiligo. 
 
2. Regulatory T cells in vitiligo 
 
An initial indication that a defect in Treg cell function could contribute to the progressive 
depigmentation of the skin came from studies of murine melanoma where the depletion of 
Tregs caused the activation of anti-melanoma cytotoxic T cells that destroyed melanoma 
tumours but also generated vitiligo as a side-effect [16]. More recently, repigmentation in a 
mouse model of spontaneous epidermal depigmentation was found to be accompanied by an 
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increased Treg cell infiltration, suggesting their importance in preventing an ongoing immune 
response against melanocytes [17]. To date, several studies have indicated perturbations in 
Treg cell numbers and/or function in vitiligo patients [10-27]. Such alterations might lead to the 
higher levels and activation of cytotoxic T cells (Fig. 1) which have been reported in individuals 
with the disease [10,11]. Currently, however, studies examining any reciprocal relationship 
between CD4
+
CD25
+
FoxP3
+
 Tregs and CD8
+
 in vitiligo progression are lacking. 
 
2.1. Regulatory T cell numbers 
 
Several studies have been carried out to look for alterations in Treg cell numbers in 
vitiligo (Table 1) [10-23,26,27]. Assessment of circulating Tregs by flow cytometric analysis has 
revealed a decrease in their numbers in vitiligo patients compared to controls [10,11,13]. 
Reduced peripheral Treg cell numbers have also been reported in early age-of-onset patients 
(1-20 years) compared to those with late onset vitiligo, and decreased circulating Treg cell 
counts have been demonstrated in patients with active vitiligo as compared to those with 
stable disease [11]. Moreover, a striking reduction in the number of Tregs in the marginal and 
lesional skin of vitiligo patients has been observed [18,19].  
Interestingly, some studies have demonstrated that peripheral or lesional skin 
CD4
+
CD25
+
FoxP3
+ 
Treg cell numbers remain unaltered in vitiligo [20,21,23], and even that 
either may be increased [10,22].  
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2.2. Regulatory T cell function 
 
Significant reductions in the function of peripheral Tregs have been demonstrated in 
progressive vitiligo using assays which measure how well these cells can inhibit the proliferation 
of and cytokine production from stimulated autologous CD8
+
 T cells (Table 1) [10, 13]. The 
possible causes of Treg cell functional defects in vitiligo have been investigated and these are 
summarised below. 
 
2.2.1. Forkhead box P3  
The transcription factor Forkhead box P3 (FoxP3) is a specific marker for Tregs and 
serves as the dedicated mediator governing Treg cell development and function [28-30]. FoxP3 
down-regulates T cell activation and cytokine genes (e.g., encoding IL-2, IL-4), and upregulates 
immunosuppressive cell-surface molecules (e.g., CD25, CTLA-4) and, in doing so, contributes to 
both the hyporesponsive and suppressive Treg cell phenotype [31,32]. FoxP3 suppresses the 
effector functions of T helper cells by directly inhibiting the activity of two key transcription 
factors, nuclear factor of activated T cells (NFAT) and nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-ʃ ?, which are essential for cytokine gene expression and T cell 
functions [30]. In mice, the depletion of FoxP3
+
 Tregs leads to the induction of autoimmunity by 
specifically ablating Tregs [33]. 
Several observations indicate that there is a defect in FoxP3 expression in vitiligo 
patients that could impair the function of Treg cells. Firstly, FoxP3 expression is significantly 
decreased in CD4
+
CD25
+
 Tregs from vitiligo patients compared to controls [11]. Secondly, the 
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mean percentage area of FoxP3-positive immunostaining in lesional skin and the levels of 
FoxP3-positive cells in the peripheral blood are significantly lower in vitiligo patients compared 
to controls [24]. Finally, FOXP3 mRNA levels in lesional and perilesional skin are significantly 
reduced in vitiligo patients when compared with skin from healthy individuals [25]. In contrast, 
significantly higher levels of FOXP3 mRNA expression have been found to occur in lesional 
vitiligo skin compared to non-lesional vitiligo skin [13], suggesting the recruitment of Tregs into 
the affected site to balance the autoimmune response. 
Several studies have indicated that genetic defects in FOXP3 may lead to its altered 
levels and functionality and, indeed, autoimmune disorders have been related to various 
deleterious mutations in FOXP3 [34-38]. With respect to vitiligo, polymorphisms of FOXP3 have 
been associated with predispostion to the development of the disease (Table 2) [39-41]. 
 
2.2.2. Cytotoxic T lymphocyte antigen-4  
Cytotoxic T lymphocyte antigen-4 (CTLA-4 or CD152) is a T cell surface molecule involved 
in regulation of T cell activation and plays a critical role in the maintenance of tolerance to self-
antigens [42]. Moreover, knock-out mouse models have shown that CTLA-4 plays a key role in 
Treg cell function and maintaining peripheral tolerance [43-45]. It is therefore not surprising 
that the abnormal function of the molecule has been implicated in the aetiology of several 
autoimmune diseases including vitiligo [46-48]. Indeed, both soluble (sCTLA-4) and full-length 
(flCTLA-4) CTLA-4 mRNA have been found at decreased levels in vitiligo patients, which could 
perturb the normal suppressive capacity of Tregs [46]. Vitiligo has also been associated with the 
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presence of the  ? ?ƵŶƚƌĂŶƐůĂƚĞĚƌĞŐŝŽŶd ? ?'G (rs3087243) allelic variation of CTLA-4, this in 
turn being correlated with the reduction in CTLA-4 mRNA levels [46]. 
 
2.2.3. Transforming growth factor-ɴ 
Transforming growth factor-ɴ is important for imposing a regulatory phenotype on the 
Treg cell subset [49-51]. Studies have reported that TGF-ɴ has the ability to induce CD4+CD25- 
cells to become CD4
+
CD25
+
 Tregs in vitro [52,53], and TGF-ɴcan induce FoxP3 expression in 
iTregs [54,55]. Additionally, other studies have clearly demonstrated that the suppressive 
capacity of FoxP3
+
 Tregs in vivo is via a TGF-ɴ-dependent mechanism [56,57]. 
A number of studies indicate that decreased TGF-ɴƐĞƌƵŵĂŶĚƚŝƐƐƵĞůĞǀĞůƐĂƌĞĨŽƵŶĚin 
vitiligo patients, and this could have a deleterious effect upon Treg cell function in these 
individuals [58-60]. In addition, serum concentrations of TGF-ɴ have been shown to be 
decreased in cases of active but not stable vitiligo, indicating that lower levels of the cytokine 
are positively correlated with disease progression [61]. Furthermore, the reduced levels of TGF-
ɴ secreted by vitiligo patient Tregs are negatively correlated with the percentage of 
depigmented body area [62]. Interestingly, three single nucleotide polymorphisms of the TGF-ɴ
receptor 2 gene (TGFBR2) (rs2005061, rs3773645, rs3773649) are associated with vitiligo 
susceptibility [63], although it is not yet clear how these allelic variants influence the expression 
of TGF-ɴ. 
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2.2.3. Interleukin-10 
Tregs induced by IL-10 contribute to Treg cell-mediated immunosuppression principally 
by producing IL-10 [64-65]. Several pieces of evidence suggest a role for IL-10 in the 
pathogenesis of vitiligo. For example, decreased IL-10 levels have been demonstrated in cases 
of active but not stable vitiligo, suggesting that IL-10 might play an important role in disease 
progression [61]. In addition, our recent study has also suggested a decrease in IL-10 mRNA 
expression in vitiligo patients as compared to healthy controls (Dwivedi et al., unpublished 
results). Interestingly, increased IL-10 expression in vitiligo lesions has been shown to occur 
after topical tacrolimus treatment suggesting that the inhibition of melanocyte destruction is 
triggered by unchecked Th1 pathways in vitiligo [66]. Furthermore, genetic susceptibility to 
vitiligo has been reported to be associated with polymorphisms in the IL-10 gene in Saudi 
patients: the GG genotype at -1082 and the CC genotype at positions -592 and +819 were 
significantly more prevalent in vitiligo patients compared to controls [67]. However, it has not 
been established whether these promoter polymorphisms play a role in the altered IL-10 
expression.  
Animal models also indicate a role for IL-10 in vitiligo development. Studies of Smyth 
line chickens, an animal model for human autoimmune vitiligo, have demonstrated that 
elevated leukocyte infiltration in early and active vitiligo is accompanied by increased levels of 
cytokine expression, especially in interferon (IFN)-ɶ ?/>-10, and IL-21 [68]. Recently, in a mouse 
model of spontaneous melanoma, Treg cell-depletion and IL-10 neutralisation led to an 
increased occurrence of vitiligo which correlated with a decreased incidence of melanoma 
metastases [69].  
14 
 
2.2.4. Cell-homing capacity 
Klarquist et al. [23] reported a discrepancy between the relative abundance of Treg cells 
present in the circulation of vitiligo patients as compared to their skin. The authors suggested 
that this may be explained by a failure of Tregs to migrate into the skin. However, their 
experiments demonstrated that expression of receptors previously shown to dictate homing of 
Treg cells to the skin compartment was similar among the patient and control populations. 
Further investigations indicated that reduced expression of chemoattractant CCL22 within 
vitiligo patient skin is primarily responsible for impaired migration of Tregs into the tissue. 
 
3. Regulatory T cells as therapeutic targets for vitiligo 
 
The studies discussed above certainly render Treg cells as crucial immune regulators 
involved in vitiligo pathogenesis. Approaches to correct defects in numbers or functions of 
Tregs may, therefore, be valuable in the treatment of autoimmune vitiligo.  
 
3.1. Adoptive transfer therapy using regulatory T cells  
 
Systemic treatments for autoimmune disorders directed at augmenting Treg cell 
activities in vivo may be associated with significant off-target effects, including a generalised 
immunosuppression that may compromise beneficial immune responses. Therefore, the 
adoptive transfer of in vitro-generated, antigen-specific iTregs is a potential therapy option for 
autoimmune disorders. Treg cells can indeed be expanded ex vivo with allogeneic B cells [70] 
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and these express very high levels of FoxP3, maintain an anergic phenotype, and are potent 
suppressors capable of inhibiting activated T cell responses [70]. To generate the sufficient 
antigen-specific Tregs for adoptive transfer, Brusco et al. [71] have developed a novel technique 
involving lentiviral T cell receptor gene transfer into in vitro expanded polyclonal nTreg cell 
populations, indicating the feasibility of major histocompatibility complex class I-restricted T 
cell receptor transfer as a promising strategy to redirect the functional properties of Tregs and 
provide for a more efficacious adoptive Treg cell therapy. 
 Several previous studies have indeed demonstrated that the adoptive transfer of iTregs 
can suppress disease development in a lupus syndrome-like model [72, 73], experimental 
autoimmune encephalomyelitis, an animal model of multiple sclerosis [74], an autoimmune 
gastritis model [75-76], spontaneous development of type 1 diabetes in mice [77], Th1-
mediated colitis [78], Th17-mediated diseases [79], and house dust mite-induced allergic 
pathogenesis in an asthmatic mouse model [80]. 
 Recently, Chatterjee et al. [81] have reported the first animal study proposing Tregs as a 
therapeutic for vitiligo. Using transgenic mice that carry T cells with a human leukocyte antigen 
(HLA)-A2-restricted human tyrosinase peptide-reactive T cell receptor and that develop 
spontaneous vitiligo from an early age, adoptively transferred Tregs were found to induce a 
lasting remission of vitiligo in mice treated at the onset of disease, or in mice with established 
disease. The authors concluded that reduced regulatory responses are pivotal to the 
development of vitiligo in disease-prone mice, and that a quantitative increase in the Treg cell 
population may be therapeutic for vitiligo patients with active disease. 
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3.2. Adoptive transfer therapy using heat-shock protein-specific regulatory T cells  
 
Heat-shock proteins play an important role in immune activation and may participate in 
dysregulation of immune homeostasis. The presence of heat-shock protein activates dendritic 
cells which respond by recruiting immune cells to the site of inflammation. Recently, a role for 
induced heat-shock protein has been reported in the pathogenesis of vitiligo revealing its 
potential as a significant therapeutic target for the disease [6,82,83]. Indeed, the suppressive 
capacity of heat-shock protein-specific Treg cells has been demonstrated in studies performed 
in animal models and in human clinical trials for autoimmune and autoinflammatory diseases 
[84-86], but not yet for vitiligo. 
 
3.3. Use of probiotics for the induction of regulatory T cells  
 
The administration of microbes or microbial metabolites for the prevention and 
treatment of aberrant immune response is gaining importance [87].  The term probiotic refers 
ƚŽ ‘ůŝǀŝŶŐŵŝĐƌŽŽƌŐĂŶŝƐŵƐǁhich, when consumed in adequate amounts, confer a health effect 
ŽŶƚŚĞŚŽƐƚ ?[88]. The protective effects associated with these microbes are mediated by 
multiple mechanisms involving T cells, dendritic cells and epithelial cells. An increasingly 
recognised feature of immunoregulatory microbes is their ability to induce Treg cells [87]. It has 
been demonstrated that oral consumption of Bifidobacterium infantis 35624 is associated with 
enhanced IL-10 secretion and FoxP3 expression in human peripheral blood [89]. Murine studies 
have demonstrated that B. infantis administration results in an increase in CD4
+
CD25
+
FoxP3
+
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lymphocytes [90]. Moreover, it has been seen that, in vitro human dendritic cells stimulated 
with B. infantis selectively promoted the upregulation of FoxP3 expression in naïve lymphocytes 
[89]. Furthermore, B. infantis has been demonstrated to reduce symptom severity in patients 
with inflammatory bowel syndrome in two placebo-controlled human clinical studies [91,92]. 
Thus, the induction of FoxP3
+
 Treg cells by B. infantis seems to be a robust and reproducible 
phenomenon, which could be useful in the treatment of autoimmune diseases including vitiligo. 
Recently, it has been suggested that probiotic (Lactobacillus reuteri DSM 17938)-
facilitated development of Tregs might play an important role in the prevention of necrotising 
enterocolitis, and Feleszko et al. [93] showed that probiotic bacteria (L. rhamnosus GG or 
Bifidobacterium lactis Bb-12) inhibit subsequent allergic sensitisation and airway disease in a 
murine model of asthma by inducing Tregs associated with increased TGF-ɴƉƌŽĚƵĐƚŝŽŶ ? 
Furthermore, the probiotics mixtures (L. acidophilus, L. casei, L. reuteri, ŝĮĚŽďĂĐƚĞƌŝƵŵ, and 
Streptococcus thermophilus) induce the generation of CD4
+
FoxP3
+
 Tregs from the CD4
+
CD25
-
 
population and increased the suppressor activity of naturally occurring CD4
+
CD25
+
 Tregs in mice 
[94]. Interestingly, the report suggests that conversion of T cells into FoxP3
+
 Tregs is directly 
mediated by regulatory dendritic cells that express high levels of IL-10 and TGF-ɴ. In addition, 
administration of the probiotics had therapeutical effects in experimental inflammatory bowel 
disease, atopic dermatitis and rheumatoid arthritis [94]. Recently, the effects of L. rhamnosus 
on the progression of the clinical signs of atopic dermatitis to allergic asthma has been shown 
by suppressing Th2 and Th17 responses via CD4
+
CD25
+
FoxP3
+
 Tregs [95]. Finally, a mixture of 
three Lactobacilli strains (L. paracasei DSM 13434, L. plantarum DSM 15312 and DSM 15313) 
suppressed the progression and reversed the clinical and histological signs of experimental 
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autoimmune encephalomyelitis by inducing CD4
+
CD25
+
FoxP3
+
 Tregs and enhancing production 
of serum IL-10 and TGF-ɴ [96]. 
Overall, these findings indicate the therapeutic potential of oral administration of a 
combination of probiotics in the management of autoimmune diseases and they therefore have 
similar potential for the treatment of vitiligo. However, further animal as well as human studies 
are required to provide evidence for the possible use of probiotics in the therapy of skin 
depigmentation. 
 
3.4. Other approaches used for the induction of regulatory T cells 
 
A number of other approaches have been used for the induction of Treg cells, and these 
are summarised in this section. However, their full potential for treatment of autoimmune 
diseases including vitiligo remains to be explored. 
 
3.4.1. Acidic polysaccharide of Panax ginseng 
An acidic polysaccharide of Panax ginseng (APG) has multiple immunomodulatory 
effects through instigating the production of a variety of anti-inflammatory cytokines. Studies 
have shown that APG significantly ameliorates the progression of experimental autoimmune 
encephalomyelitis by inhibiting the proliferation of autoreactive T cells and promoting the 
generation of immunosuppressive Tregs through the activation of FoxP3 [97]. Recently, Ahmad 
et al. [98] showed that 5-aminoisoquinolinone treatment significantly up-regulated the number 
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of Tregs, IʃB (NF-ʃB inhibitor)-ɲ levels and mRNA expression of anti-inflammatory mediators, 
thereby reducing the arthritis scores in adjuvant-induced arthritis in mice. 
 
3.4.2. Interleukin-5  
Tran et al. [99] have shown that IL-5 is able to promote the induction of antigen-specific 
CD4
+
CD25
+
 Tregs that suppress autoimmunity. In particular, treatment of experimental 
autoimmune neuritis with IL-5 markedly reduced the infiltration of CD4
+
 (Th1 and Th17) and 
CD8
+
 T cells, and macrophages in nerves with expansion of antigen-specific CD4
+
CD25
+
FoxP3
+
 
Tregs. Moreover, the depletion of CD25
+
 Tregs or blocking of IL-4 abolished the benefits of IL-5 
treatment [99]. Overall, the study suggested IL-5 therapy may be able to induce antigen-specific 
tolerance in autoimmune disease. 
 
3.4.3. Interleukin-2 and interleukin-2 receptor  
Several observations have suggested that novel targets for Treg cell targeted treatment 
for autoimmune disease may lie within the IL-2/IL-2 receptor (R) pathway. Recently, Rouse et 
al. [100] demonstrated a role for IL-2 in the activation and expansion of Tregs in the 
amelioration of experimental autoimmune encephalomyelitis. Furthermore, defects in IL-2R-
signaling have been shown to contribute to the diminished maintenance of FoxP3 expression in 
Tregs in patients with type 1 diabetes [101]. In addition, allogenic stem cell transplantation was 
found to lead to full recovery from primary biliary cirrhosis where peripheral blood lymphocytes 
were completely deficient in the ɲ-subunit of the IL-2R (CD25) [102]. 
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 3.4.4. Self antigen-derived peptides 
Recent experimental work and preclinical studies have provided proof-of-concept for 
the induction of self-tolerance through the modulation of Tregs using self antigen-derived 
peptides which then promote suppression of hyperactive CD4
+ 
T cells and the production of 
pathogenic autoantibodies [103]. Interestingly, cytokine-like vasoactive intestinal peptide 
treatment to human CD4
+
CD25
-
 T cells resulted in the induction of an anergic CD4
+
CD25
+
FoxP3
+ 
T cell subset displaying potent regulatory activities against allospecific effector T cells [104]. 
This study suggested that alloantigen-specific vasoactive intestinal peptide-generated Tregs 
could be a valuable tool in therapeutic interventions to promote immunotolerance toward 
allogeneic grafts [104]. Analogous approaches could be developed for specific autoimmune 
diseases. 
 
3.4.5. Anti-CD3 monoclonal antibody 
The stimulation of T cell receptors with modified anti-CD3 monoclonal antibody has 
been applied to expand the CD8
+
 T cell population and induce CD8
+
CD25
+
 Tregs in patients with 
type 1 diabetes [105]. The study highlighted the clinical efficacy of this method of treatment of 
an autoimmune disease which prevented the loss of insulin production over the first two years 
of the disease and reduced insulin usage. 
 
3.4.6. Granulocyte-macrophage colony-stimulating factor 
Sheng et al. [106] showed that the treatment with granulocyte-macrophage colony-
stimulating factor (GM-CSF) resulted in amelioration of experimental autoimmune myasthenia 
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gravis, accompanied by a down-regulation of autoreactive T cell and pathogenic autoantibody 
responses, a mobilisation of dendritic cells with a tolerogenic phenotype, and an expansion of 
Tregs that potently suppressed acetylcholine receptor-stimulated T cell proliferation in vitro. 
The study provided evidence that the mobilization of antigen-specific Tregs in vivo using 
pharmacologic agents, like GM-CSF, can modulate ongoing immune responses against specific 
antigens capable of suppressing antibody-mediated autoimmunity. 
 
3.5. B cell-mediated pathways 
 
It is known that B cells participate in the immune system through antibody production. 
Interestingly, Walters et al. [107] have recently reported that intrathymic B cells are involved in 
production of CD4
+
FoxP3
+
 nTregs. Such information offers the possibility of using the B cell-
mediated pathway of nTreg cell generation in the Treg cell-mediated therapy of vitiligo. 
 
3.6. Regulatory T cell/Th17 cell balance 
 
The transcription factors STAT5 and STAT3 are known to control the differentiation of 
Tregs and Th17 cells, respectively. Inhibiting STAT3 using siRNA has been shown to significantly 
increase the proportion of Treg cells and decrease the proportion of Th17 cells in the CD4
+
 T cell 
population from the peripheral blood and synovial fluid of patients with rheumatoid arthritis 
[108,109]. The inhibition of STAT5 has the counter effects [108,109]. In the same study, no 
change was found to be induced by STAT3 or STAT5 siRNA in the production of Th1 versus Th2 
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signature cytokines [108], suggesting that these signalling pathways could provide novel target 
molecules for the control of Treg cells in the treatment of autoimmune disease, including 
vitiligo. 
 
3.7. Enhanced killing activity of regulatory T cells 
  
An alternative approach for using Treg cells therapeutically has been to enforce their pro-
apoptotic activity by decorating them with Fas-L protein [110]. The Fas-L-labelled Tregs showed 
sustained inhibitory activity in relation to T cell proliferation in vitro and were also found to be 
efficient in preventing the progression in mouse models of autoimmune insulitis and chronic 
colitis [110]. Though promising, the efficacy of such an approach has yet to be studied in 
relation to the treatment of human autoimmune disorders including vitiligo. 
 
4. Conclusions 
 
The exact role of Tregs in the development of vitiligo has yet to be established 
unequivocally. Particularly, there are still conflicts in the data regarding Treg cell numbers and 
function in vitiligo patients. Future studies will reveal detailed mechanisms by which Treg cells 
are involved in maintaining tolerance against pigment cell-specific antigens, such that 
alternative therapeutic approaches which could manipulate Treg cells and specifically dampen 
B and T cell autoreactivity towards melanocytes without affecting general immunity may be a 
way forward.  
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Take-home messages 
x Vitiligo patients present with defects in the function and numbers of regulatory T cells 
which may lead to increased levels of CD8
+
 T cells with anti-melanocyte activity. 
x Antigen-specific adoptive transfer of Tregs and other approaches for inducing Treg cells 
seem to be efficient in ameliorating autoimmune disease, and thus may also serve as 
therapeutics for vitiligo. 
x Further studies for determing the exact role of Tregs in the pathogenesis of vitiligo are 
required to pave the way for improved treatments. 
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Table 1. 
 
Quantitative and functional status of Treg cells in vitiligo patients. 
Treg cell numbers 
 
Decreased in blood 
and increased in skin 
 
 
Decreased in blood 
 
 
 
Unaltered in skin and 
decreased in blood of 
active cases only 
 
Decreased in skin 
 
 
Decreased in skin 
 
Unaltered in skin 
 
Unaltered in blood 
 
Increased in blood 
 
 
Decreased in skin and 
unaltered in blood 
 
 
Not analysed 
 
 
Not analysed 
 
Increased in blood 
 
 
Decreased in blood 
Treg cell function 
 
Lower suppressive capacity of Tregs 
toward CD8
+
 T cells and increased IFN-ɶ
and tumour necrosis factor-ɲůĞǀĞůƐ 
 
Decreased FoxP3, CTLA-4 and IL-10 
levels  
 
 
Lower suppressive capacity of 
peripheral Tregs toward CD8
+
 T cells 
and decreased FoxP3 expression in skin 
 
Not analysed 
 
 
Not analysed 
 
Not analysed 
 
Not analysed 
 
Not analysed 
 
 
Normal suppressive capacity of 
peripheral Tregs 
 
 
Decreased FoxP3 expression in blood 
and skin 
 
Decreased FoxP3 expression in skin 
 
Reduction in peripheral Tregs after NB-
UVB phototherapy 
 
Not analysed 
Reference 
 
[10]  
 
 
 
[11]  
 
 
 
[13]  
 
 
 
[18]  
 
 
[19]  
 
[20]  
 
[21]  
 
[22]  
 
 
[23]  
 
 
 
[24]  
 
 
[25]  
 
[26]  
 
 
[27]  
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Table 2. 
 
Genetic polymorphisms of FOXP3 studied in vitiligo. 
 
 
Polymorphism 
 
rs2232365 (A/G promoter) 
rs3761548 (A/C promoter) 
rs3761547 (A/G promoter) 
rs11798415 (A/T promoter) 
rs11798415 (A/T promoter) 
Association 
 
P = 0·004  
P = 0·033 
P = 0.002 
P = 1.8 x 10
-3
  
P = 5.8 x 10
-4
 
Population 
 
Han Chinese 
Han Chinese 
Indian 
Non-Hispanic white 
Non-Hispanic white 
Reference 
 
[39]  
[39]  
[40]  
[41]  
[41]  
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Figure legend 
Fig. 1. Proposed role of regulatory T cells in melanocyte destruction in vitligo. The schematic 
representation indicates the potential Treg cell defects which may lead to melanocyte loss in 
vitiligo. In particular, the decreased number of Tregs, which may result from defects in positive 
or negative selection in the thymus leading to a peripheral imbalance of Tregs or genetic 
susceptibility leading to abnormal Treg cell development and function, fails to suppress the 
increased number of autoreactive CD8
+
 and CD4
+
 T cells. The increase in CD8
+
 T cells may then 
destroy melanocytes through the granzyme B or perforin pathway or through cognate help via 
cytokines such as IL-6 and IL-13 resulting in melanocyte loss through apoptosis. Tregs not 
capable of suppressing autoreactive CD8
+
 T cells could also lead to melanocyte loss: the 
suppressive capacity of Tregs can be diminished by decreased expression of Treg cell-related 
proteins such as FoxP3, IL-10, TGF-ɴ and CTLA-4. Genetic defects in these genes may result in 
altered expression of these proteins. Moreover, the perturbed homeostasis of calcium in vitiligo 
signifies the alteration of calmodulin and calcimeurin activation which may result in altered 
NFAT expression and activation leading to a reduction in the suppressive capacity of Tregs. 
Moreover, deficient IL-2 production by T effector cells leads to decreased Treg cell numbers or 
function as low surface CD25 expression delivers deficient IL-2 signals resulting in impaired 
survival and function of resident Tregs. Apart from CD8
+
 T cells, increased CD4
+
 T cells can also 
lead to activation of CD8
+
 T cells which will not be suppressed by defective Tregs, thus leading 
to a hyper-autoreactive T cells response towards melanocytes. The unknown triggering factors 
such as altered melanocyte antigens, neo-antigens and defective apoptosis may serve as the 
activators of autoreactive B cells and T cells resulting into melanocyte loss. However, if the 
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ongoing immune response towards melanocytes is not checked by Tregs, then the potential 
loss of melanocytes can result in vitiligo. 
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